Zebrafish Models of Prader-Willi Syndrome: Fast Track to Pharmacotherapeutics

Emma D. Spikol, Caroline E. Laverriere, Maya Robnett, Gabriela Carter, Erin Wolfe, and Eric Glasgow*
Department of Oncology, Georgetown University Medical Center, 4000 Reservoir Road, N.W., Washington, DC 20057, USA

Abstract
Prader-Willi syndrome (PWS) is a rare genetic neurodevelopmental disorder characterized by an insatiable appetite, leading to chronic overeating and obesity. Additional features include short stature, intellectual disability, behavioral problems and incomplete sexual development. Although significant progress has been made in understanding the genetic basis of PWS, the mechanisms underlying the pathogenesis of the disorder remain poorly understood. Treatment for PWS consists mainly of palliative therapies; curative therapies are sorely needed. Zebrafish, Danio rerio, represent a promising way forward for elucidating physiological problems such as obesity and identifying new pharmacotherapeutic options for PWS. Over the last decade, an increased appreciation for the highly conserved biology among vertebrates and the ability to perform high-throughput drug screening has seen an explosion in the use of zebrafish for disease modeling and drug discovery. Here, we review recent advances in developing zebrafish models of human disease. Aspects of zebrafish genetics and physiology that are relevant to PWS will be discussed, and the advantages and disadvantages of zebrafish models will be contrasted with current animal models for this syndrome. Finally, we will present a paradigm for drug screening in zebrafish that is potentially the fastest route for identifying and delivering curative pharmacotherapies to PWS patients.

Keywords
neuroendocrine; oxytocin; zebrafish

1. Introduction
Prader-Willi syndrome (PWS) is a complex neurogenetic disorder, which results in cognitive and neuroendocrine dysfunction. Individuals with PWS present a spectrum of clinically observed phenotypes. Possibly the most debilitating symptom is insatiable appetite, which
often leads to chronic overeating and obesity. Between the ages of 4.5 and 8, children with PWS experience rapid onset of hyperphagia and obesity [1-3]. While behavioral therapy can mitigate weight gain, complications from obesity are the leading cause of morbidity in PWS [4]. Patients also suffer from growth hormone (GH) deficiency resulting in decreased growth velocity and short stature if untreated. GH treatment during childhood allows patients to reach full height [5]. Older children and adults have hypoplastic genitalia and dysmorphic features including small hands and feet, flat surface of the ulnar side of hands and inner legs, a narrow forehead, almond-shaped eyes and a downturned mouth. Sleep-disordered breathing and daytime hypersomnolence are also associated with PWS. PWS individuals are cognitively disabled, with an average IQ of 65 [1]. Finally, the disorder causes behavioral abnormalities such as skin picking and tantrums. Comorbidity with neuropsychiatric disorders is high. Current treatment options for PWS consist of hormone administration and behavioral therapy (Table 1) [1,4,6,7].

The genetic basis of PWS is an alteration in the paternally inherited allele of the imprinted chromosome 15q11–q13 region. Although it remains unclear how genetic defects at 15q11–q13 result in the clinical manifestations of PWS, it is likely that hypothalamic dysfunction underlies many of these symptoms [4]. Studies of PWS biology are likely to bring about a deeper understanding of the molecular, cellular, physiological and behavioral basis of this syndrome, and eventually bring targeted, curative therapies to PWS patients. Already, several mouse models of PWS have been created, and despite failure to recapitulate all aspects of PWS, they have proved very informative [6]. Several mouse models, particularly those with inactivated genes implicated in PWS-like disorders, support hypothalamic dysfunction as a major feature of PWS. However, notwithstanding the utility of mouse models for understanding the pathobiology of PWS, mice are ill-suited for high-throughput screens.

Over the last few decades, zebrafish have emerged as an excellent model to study vertebrate development and human disease. Zebrafish offer many advantages over other vertebrate species. In particular, their fecundity and small adult body size allows them to be housed at high densities in a laboratory setting. Furthermore, zebrafish reach sexual maturity at three months, akin to mice, but embryonic development occurs more rapidly than in mice with most zebrafish organs and glands developed by five days post-fertilization. As vertebrates, zebrafish have many of the same genes, cells, tissues, glands, organs systems and body plans as their mammalian counterparts [8,9]. Moreover, although they lack much of the highly developed mammalian cortical brain regions, evolutionarily older structures including the neuroendocrine system are remarkably conserved. Zebrafish embryos are capable of fitting into 96-well plates, in addition to their relative translucency, making them ideal candidates for high-throughput screens and advanced imaging techniques. Finally, the zebrafish genome-sequencing project, which began in 2001, found that approximately 70% of human genes have at least one zebrafish ortholog with 82% of known human disease genes having a zebrafish ortholog [10].

Here, we summarize progress in understanding PWS pathobiology in light of creating zebrafish models for this syndrome. We discuss three investigative strategies commonly used in zebrafish research, including: (1) the production of gene-knockout models paired with
high-throughput screens to pinpoint drug targets; (2) the use of large scale mutagenesis screens to identify and investigate endophenotypes that are relevant to PWS; and (3) the use of high throughput drug screens to identify compounds with activity specific to neuronal populations and behaviors affected by PWS (Figure 1). This last strategy may provide the fastest route for identifying curative pharmacotherapeutic compounds when used to screen libraries of FDA approved drugs.

2. Discussion

2.1. Genetics

The genetic basis of PWS is the loss of imprinted genes in the 15q11–q13 region, which are exclusively expressed from the paternal chromosome. Loss of the paternally expressed genes associated with PWS can occur in multiple ways. In about two thirds of PWS cases, there is a deletion of 4–4.5 Mb in the paternal copy of the 15q11–q13 region. In about 25% of cases, the cause is uniparental disomy resulting in the inheritance of two copies of chromosome 15 from the mother. In fewer than 3% of cases, PWS is caused by a submicroscopic deletion or epimutation of a sequence known as the imprinting center (IC). Finally, rare cases result from chromosomal translocations or rearrangements [1]. Imprinted PWS-associated genes located in the 15q11–q13 region are subject to varying degrees of conservation in mouse and zebrafish. In mouse, chromosome 7 B/C is a syntenic imprinted region containing several orthologs of PWS-associated genes. The imprinted PWS gene cluster is absent in fish, likely arising in the mammalian lineage. Nonetheless, several genes have putative orthologs in zebrafish, including makorin ring finger protein 3 (MKRN3); MAGE family member L2 (MAGEL2); necdin, MAGE family member (NDN); and small nuclear ribonucleoprotein polypeptide N (SNRPN) (Table 2).

MKRN3, along with MKRN1, MKRN2, and MKRN4, is a member of a unique family of ring finger containing proteins with ubiquitin ligase and transcriptional coregulatory functions. In mice, Mkrn3 is highly expressed in the fetal arcuate nucleus, and in humans, MKRN3 mutations have been implicated in precocious puberty, thus implicating this gene in hypothalamic function. MKRN3 in mammals likely arose by retrotransposition of the paralogous MKRN1 gene [12,13]. Therefore, zebrafish lack the mkrn3 gene, with the most similar gene being mkrn1. Unlike the other zebrafish orthologs for PWS-associated genes, this ancestral gene has extensive synteny with both mouse and human [14].

MAGEL2 and NDN code for MAGE proteins, a large family of poorly understood ubiquitin ligase proteins. The MAGE family is unusual in mammals in that there have been multiple species specific expansions of various MAGE family members, with over 50 genes in humans. In contrast, non-mammalian species such as zebrafish have a single representative of the MAGE family. Thus, in zebrafish, the singular MAGE family gene, ndnl2, is most similar to both MAGEL2 and NDN [15].

SNRPN encodes a bicistronic transcript. One product, Snrpn Upstream Reading Frame (SNURF), is a non-coding RNA of unknown function. The other encodes SmN, a LSm family protein, which is thought to be involved in pre-mRNA processing. The SNRPN gene also contains a sequence known as the imprinting center (IC), which is required for silencing
the maternal allele [16]. Zebrafish do not have a sarpn gene, they do however have an ortholog of SNRBP, which likely gave rise to SNRPN by duplication in the mammalian lineage [12]. The amino acid sequence conservation among zebrafish sarpb and human SNRPN very high (93%; Table 2), especially in the LSm superfamily conserved domain, which is involved in RNA processing.

There are some differences in the imprinted PWS region between mice and humans. In mice, an imprinted gene known as Peg12 lies within the PWS region. Peg12 is a member of the glycogen synthase kinase 3 binding protein (Gbp) family, with presumed functions in the regulation of Wnt signaling. The most closely related human gene, Frequently Rearranged In Advanced T-Cell Lymphomas 1 (FRAT1), is located on chromosome 10, while the orthologous mouse Frat1 gene is located on chromosome 19 and is not known to be imprinted. Knockout of either peg12 or Frat1 had no phenotype so the physiological role of these genes is unclear. In zebrafish, only a single ancestral gene, gbp, is present and, although a mutant exists, it has not yet been characterized.

An additional difference is that in humans, but not mice, the nuclear pore-associated protein NPAPI gene is found within the imprinted PWS region. NPAPI likely arose in primates after several rounds of retrotransposition of the ancestral POM121 gene [17]. Thus, like mice, zebrafish do not have an npap1 gene, however, they both do have the ancestral pom121 gene. Neither mouse nor zebrafish pom121 mutants have been characterized.

In addition to the protein coding genes discussed above, the PWS-region contains multiple gene clusters, called SNORDs, encoding small nucleolar RNAs (snoRNAs) belonging to the C/D box group [18,19]. For the SNORD107, SNORD64, SNORD115 and SNORD116 clusters, orthologous groups exist in mouse, although copy numbers vary. However, no mouse orthologs have been identified for SNORD108, SNORD109A or SNORD109B (Table 2). Although SnoRNA genes are typically conserved sequences, those in the PWS region belong to a group of eutherian-specific imprinted SnoRNAs for which homologs in non-eutherian vertebrates have yet to be identified [11]. While many SnoRNA genes can be found in zebrafish, none identified thus far are likely to be orthologous to PWS-region SnoRNAs.

In summary, the genes within the PWS-region primarily fall into three classes, ubiquitin ligases, RNA processing regulators and SnoRNAs. Genes in these classes regulate the expression of other genes, controlling rates of protein and RNA turnover, and influencing alternative splicing events, functions that are highly conserved in all vertebrate organisms. However, it appears that essentially all the genes in the PWS-region have arisen, and rapidly diverged, in the mammalian lineage. Consequently, although zebrafish have orthologs of the ancestral genes, they do not appear to have one-to-one orthologs of the PWS-region genes. This fact begs the question of how zebrafish could be used as models for PWS research if they don’t have PWS genes. The answer lies in the fact that dysregulation of PWS genes result in alterations in highly conserved developmental pathways, particularly evident in the hypothalamus. This is illustrated by studies of PWS-like syndromes, which implicate pathways that are highly conserved in humans, mice and zebrafish.
2.2. PWS-Like Syndromes: 6q16 Deletions

Prader-Willi-like (PWL) syndromes share features of the PWS phenotype, however the genetic basis of these rare disorders differs. The implication is that the gene functions disrupted in PWL are likely to lie in genetic pathways that are important for the development of PWS phenotypes. By extension then, drugs targeting these pathways may prove effective for PWS patients. Elucidation of these conserved pathways and identification of potential drug compounds could greatly benefit from zebrafish models.

Although a variety of deletions have been reported to cause Prader-Willi related phenotypes, the most common PWL deletion is the 6q16 deletion comprising the bHLH-PAS family transcription factor \textit{SIM1} [20-22]. \textit{Sim1} heterozygous mice display hyperphagic obesity and reduced oxytocin expression in the hypothalamus [23,24]. Oxytocin neurons that project to the hindbrain have been implicated in satiety [25,26]. Recently, a small 6q16 deletion that results in PWL as been identified. The deletion leaves \textit{SIM1} intact but deletes another gene, \textit{POU3F2}, in the oxytocin developmental pathway [27]. Importantly, the entire \textit{sim1}, \textit{pou3f2}, \textit{oxytocin} pathway has been shown to be conserved in human, mouse and zebrafish [27-35]. Together, these findings suggest a role for the oxytocinergic system in PWS symptoms and highlight the value of modeling phenotype in addition to genetic cause to uncover the developmental underpinnings of PWS.

2.3. Non Imprinted PWS Genes

Along with the imprinted PWS genes there are several non-imprinted genes located within the most common PWS chromosomal breakpoints. Four non imprinted genes, \textit{NIPA1}, \textit{NIPA2}, \textit{CYFIP1} and \textit{TUBGCP5}, are located upstream of \textit{MKRN3}. These four genes lie between the two most common upstream PWS chromosomal breakpoints. Downstream of the PWS imprinted region are two paternally imprinted genes associated with Angelman Syndrome, \textit{UBE3A} and \textit{ATP10A}. Five non imprinted genes, \textit{GABRB3}, \textit{GABRA5}, \textit{GABRG3}, \textit{OCA} and \textit{HERC2}, are then located before the most common downstream PWS breakpoint. Haploinsufficiency of these genes could modify the pathobiology of PWS in cases where they are deleted from the paternal chromosome.

Although all the non-imprinted genes appear to be important for neurological function, their potential contribution to PWS has not been well-studied. Interestingly, in contrast to the mammalian specific imprinted PWS genes, the Angelman Syndrome-related and the non imprinted PWS genes are highly conserved among vertebrates. These genes all have one-to-oneorthologs between human and zebrafish with highly conserved synteny. It appears as though the mammalian imprinted PWS genes arose primarily by duplication and transposition of ancestral genes located elsewhere in the genome, accumulating smack in the middle of this highly conserved group of neural related genes. Therefore, it is tempting to speculate that these non imprinted genes influence PWS. Studies in zebrafish have high potential for shedding light on the function of these genes as their expression could be easily manipulated in this organism.
2.4. Mouse Models

In mice, the existence of a syntenic region containing orthologs of PWS-related imprinted genes has allowed for the generation of mouse models with large deletions spanning the entire PWS region in the hopes of recapitulating the complex phenotype of Prader-Willi patients. However, neonatal death in these models has precluded the study of the hyperphagia phenotype, which is a leading cause of morbidity in PWS. The first of these mutants harbored a deletion of the central portion of the paternally inherited chromosome 7, and a duplication of the maternally inherited copy. These mice began to fail and died within eight days after birth [36]. Similarly, in a large deletion of all imprinted genes in the PWS-associated region in mice, offspring failed to thrive and died within a week [37] (Table 3). Although these models come closest to replicating PWS in genotype, the severity of the resulting phenotypes prohibit their use for extensive study of the disorder. Snrpn deletions of varying sizes have been studied in an attempt to clarify the role of SNRPN in PWS, and locate the region of this gene that is critical for imprinting [38]. Several of these models in which much or all of the Snrpn sequence has been deleted have produced mice that fail to thrive and die early on, precluding phenotypic analysis. Some smaller deletion models in which only parts of the Snrpn gene have been removed showed improved survival, however they did not display observable abnormal phenotypes (Table 3). Zebrafish are not amenable to this analysis as they lack a comparable PWS imprinted region.

Single gene deletion models in mice have been more successful in achieving PWS-like phenotypes that can realistically be studied. Although these gene knockouts are much less extensive than the lack of expression of the paternal ch15q11–q13 region observed in PWS, the resulting mice display a variety of endophenotypes that are reminiscent of the disorder (Table 4). Unique to the Magel2 knockout was impaired fertility and alterations in circadian rhythm, while the Ndn knockout mice suffered from respiratory distress [42-44]. Interestingly, the Ndn knockout had decreased oxytocin expression in the paraventricular nuclei of the hypothalamus [43]. Magel2 and Snord116 knockouts displayed growth retardation early in life, as is observed in PWS patients. In later life, the Snord116 knockout model was hyperphagic, while the Magel2 knockout had increased fat mass [45,46]. However, no model has recapitulated the concomitance of increased appetite and obesity, which is a prominent feature of PWS. A number of behavioral phenotypes have also been identified in the single-gene knockout models. The Magel2 and Snord116 knockouts had increased anxiety, and the Ndn-deficient mice showed improved spatial learning and memory as well as skin-scraping—a behavior commonly observed in PWS patients [43-45]. While these phenotypes are abnormal, the extent of their similarity to the cognitive, behavioral and psychiatric components of PWS remains unclear.

While relevant endophenotypes appear in mouse models with partial genetic replication of PWS, models with full PWS deletions do not survive long enough to display the main characteristics of the disorder. This suggests that differences between mouse and human PWS-regions may preclude generation of mouse models that fully recapitulate PWS. On the other hand, single-gene knockout studies in mice have begun to uncover the role of several PWS-related genes.
Zebrafish do not have one-to-one orthologs of the imprinted PWS-associated genes so direct PWS single gene knockout models cannot be generated in this organism. However, zebrafish do have orthologs of the ancestral precursors of the PWS genes. Studies of the ancestral genes in zebrafish may be highly informative for PWS pathology, as many of the PWS genes are members of multigene clusters with potential for redundant function. Because zebrafish often have a single ancestral gene, the effects of gene manipulation on neurodevelopment and function may be easier to discern.

Genes that are outside of the PWS-region but result in PWS-like phenotypes, and are thus implicated in important pathways in PWS pathobiology, present additional fruitful avenues of research. For example, mutations in SIM1, leptin receptor (LEPR), pro-opiomelanocortin (POMC), melanocortin 4 receptor (MC4R), and more recently, POU3F2 have all been associated with severe obesity, suggesting a convergence on the leptin-melanocortin pathway in association with oxytocin [25,27]. Mutations in zebrafish lepr, mcr4, and pou3f2 have been generated, although few obesity-related studies have been performed as of yet. Zebrafish however, are powerful models for investigating molecular developmental pathways so we anticipate rapid progress in this area. Knowledge gained from these studies will likely reveal important new targets for pharmacotherapies.

Identifying drugs that could rescue PWS phenotypes would provide a promising way forward in developing curative therapies for this disorder. However, mice are impractical for large-scale drug discovery. On the other hand, models generated in zebrafish, either by gene-knockouts or mutagenesis screens, which display PWS-like endophenotypes, provide ideal drug discovery platforms.

2.5. The Zebrafish Model: Conserved Neuroanatomy and Physiology

The last common ancestor of zebrafish and human was the lobe-finned fish. These fish were already highly sophisticated animals with extensive behavioral repertoires and exquisite ability to respond to environmental changes to maintain physiological homeostasis. Therefore, the human brain evolved upon this complex substrate resulting in the conservation of much of the underlying neuroendocrine and autonomic function. This observation gave rise to the idea of the primitive “reptilian brain”, an idea that was generally discarded when it became evident that the so-called primitive brain areas were extensively interconnected to higher cortical brain regions, and critically important for higher brain function. In fact, most neuromodulatory systems, which are critical targets of neuropsychiatric pharmacotherapies, arise from primitive brain areas. Conservation in primitive brain neuroanatomy and physiology is apparent in the neuroendocrine hypothalamus, and thus, has important implications for the usefulness of the zebrafish model for PWS research.

Many of the characteristics associated with PWS, including hyperphagia, temperature instability, high pain threshold, sleep-disordered breathing, and endocrine abnormalities such as growth hormone deficiency, central adrenal insufficiency, central hypothyroidism, and hypogonadism, are linked to hypothalamo-pituitary axis (HPA) dysfunction [1,47]. The evolutionarily conserved HPA, consisting of the hypothalamus and pituitary gland

*Diseases.* Author manuscript; available in PMC 2016 November 15.
(hypophysis), serves as the connection between the central nervous system (CNS) and the endocrine system, which together regulate whole-body homeostasis and reproduction [48].

The mammalian neuroendocrine hypothalamus is composed of several nuclei that contain distinct clusters of neurons that project to the pituitary. The magnocellular system consists of large AVP and OXT producing neurons located in the supraoptic nucleus (SON) and paraventricular nucleus (PVN) that project to neurohemal sites in the posterior pituitary (neurohypophysis) where these hormones are released directly into the systemic circulatory system. The parvocellular system consists of smaller neurons that control the anterior pituitary (adenohypophysis). The major nuclei of the parvocellular system are the PVN, arcuate nucleus (AR), anterior periventricular nuclei (aPV) and preoptic area (POA). Parvocellular neurons from these nuclei project to a small portal blood system releasing one or more of the following six hormones, thyrotropin releasing hormone (TRH), corticotropin releasing hormone (CRH), growth hormone-releasing hormone (GHRH), somatostatin (SST), gonadotropin-releasing hormone (GnRH), and dopamine (DA). These hormones each initiate the release of distinct hormones from the adenohypophysis into the blood stream.

The nuclei of the hypothalamus are extensively interconnected and receive diverse input from multiple CNS regions. In addition, these cells have extensive extrahypophysial projections, releasing their peptide hormones as modulatory neurotransmitters within the brain, presumably to coordinate behavior with maintenance of physiological homeostasis. This Gordian entanglement of neuronal circuitry likely ensures the exquisite control of physiologic homeostasis that is achieved by the hypothalamus. Understanding how the highly complex chemosarchitecture and circuitry of the hypothalamus coordinates brain-body communication presents an exciting challenge, and is not only important for identifying potential therapeutics for PWS, but will contribute to a wide range of neuropsychiatric conditions, such as autism, obesity, anorexia, affective, obsessive-compulsive, and anxiety disorders [49]. The multifaceted experimental advantages of zebrafish for genetic and pharmacological analysis, visualizing and manipulating brain circuits, and behavioral analyses will help meet this challenge.

A fundamental tenet of evolutionary biology is that critical structures are not reinvented, instead they are built upon [50,51]. What this means for comparison between fish and humans is that the “primitive brain”, representing the brain of the last common ancestor of teleosts and mammals, should largely be the same, particularly for core functions. Layered on top of the core functions would be extensive adaptations acquired during the incredible brain expansion that defines the path of human evolution. This is illustrated by the extensive reciprocal connectivity between the higher cortical brain regions and the hypothalamic nuclei. As the hypothalamus and other brain stem regions were already highly complex and absolutely required for survival, the underlying organization and functions of these regions would be highly conserved. On the other hand, each species must adapt to its specific environmental pressures. Therefore, one finds, as expected, specific differences between species. Along these lines, an expanding use of the zebrafish model is to help differentiate between core functions and species specific adaptations when evaluating mouse studies. If a process can be shown to occur the same way in zebrafish and mice, it is likely to be a core function, and therefore, also function in humans [27,52].
Extensive studies over the past 15 years have demonstrated remarkable conservation of brain architecture, neuroendocrine cell type, function, and molecular control of hypothalamic development between zebrafish and mammals. These studies have been recently reviewed [8,48]. In short, zebrafish have similar neuroendocrine cells producing OXT, AVP, TRH, CRH, GHRH, SST, GnRH, and DA as are seen in mammals. These neurons project similarly to the pituitary where they control the release of the same pituitary hormones as seen in mammals. In addition to the neuroendocrine cells, many other hypothalamic peptidergic neurons have been characterized in zebrafish including, melanocortin, hypocretin, and somatostatin [53-55]. Remarkably, the functions and regulation of the various endocrine axes are largely the same, taking into consideration obvious lifestyle differences. Moreover, many aspects of hypothalamic circuitry are conserved. For example, recent data suggests that a key part of the essential hypothalamic circuit controlling energy homeostasis in mammals, the melanocortin system, is conserved zebrafish [8]. Overall, zebrafish appear well suited for modeling PWS, at least based on hypothalamic endophenotypes.

2.6. Technologies for Phenotypic Analysis: PWS Endophenotypes

A variety of strategies for phenotypic analysis in zebrafish enable the study of PWS endophenotypes resulting from genetic or pharmacologic manipulations. These include omics analyses, such as RNAseq transcriptomics, quantification of fluorescence or luciferase in transgenic reporter fish, analysis of morphology using high-throughput hyperdimensional screens, and even behavioral assays [56-69].

Perhaps the most well documented endophenotypes in PWS are deficits in hypothalamic development and function. The numbers of oxytocin producing neurons, as well as circulating levels of oxytocin peptide are decreased in PWS patients. GH production is likewise reduced. In fact, GH replacement is one of the only therapies shown to improve PWS symptoms. GnRH, follicle-stimulating hormone (FSH) and luteinizing hormone (LH) perturbations are also strongly implicated in PWS. Hypocretin is involved in promoting wakefulness and regulating appetite, and the melanocortin pathway is critical for appetite control and energy expenditure. Given the high evolutionary conservation of the hypothalamus, this brain region may provide an especially fertile substrate for developing zebrafish models of PWS. Therefore, the following discussion mostly focuses on hypothalamic based endophenotypes.

Transgenic zebrafish are well suited to the detection of abnormalities in the development and regulation of neuronal populations. Especially relevant to PWS are the hypothalamic nuclei, for which several transgenic zebrafish models already exist. Zebrafish larvae expressing GFP driven by an oxytocin promoter have been used to study the effect of fetal ethanol exposure on brain development, and as a model for fetal alcohol syndrome [70]. Also, POMC producing cells, an important component of the HPA, have been tagged in transgenic zebrafish lines [71,72]. In addition, zebrafish have been generated that express fluorescent proteins in GnRH, FSH, LH, and prolactin (PRL) secreting cells, which are deficient in PWS [73,74]. Likewise, hypocretin transgenic lines have been developed and effectively used for optogenetic studies of wakefulness in zebrafish [75]. Transgenic models can be used to investigate molecular pathways involved in hypothalamic function and to discover drugs that
A recent study screened zebrafish with fluorescently marked pancreatic β-cells using automated reporter quantification in vivo (ARQ-iv) combined with robotics. In this study, 24 FDA-approved drug candidates were identified that modulated β-cell numbers [68]. Conceptually similar strategies may prove highly productive for identifying potential pharmacotherapeutics for PWS. Although there are several transgenic lines that would potentially be useful for high-throughput drug screening, new lines specifically designed for this purpose might be more productive in the end. As transgenic zebrafish are relatively easy to make, optimized designs should be pursued.

Zebrafish morphology is another potential output in PWS-related mutational or drug screening. Abnormalities in growth and body fat can be easily quantified in fish. In studies on body fat accumulation, anesthetized fish were weighed, and their body fat was quantified by computed tomography. The ratio of body fat to weight provided a measure of obesity across treatment groups [76]. Developmental deformities also represent relevant PWS endophenotypes. However, zebrafish morphology has been a problematic output for high-throughput screens since it is typically assessed by non-quantitative means. Subjective assessment of morphology may not be sensitive enough to detect minor defects in tissue architecture. Recently, however, an automated phenomics technique has been developed for high-throughput screens based on vertebrate morphology. Optical projection tomography (OPT) is capable of quickly generating and analyzing three-dimensional images of zebrafish embryos using an automated fluidics-based system. Proof of concept was illustrated by the characterization of craniofacial abnormalities in response to teratogenic chemicals [66]. As morphology screens continue to advance in sophistication, they will become valuable tools for analysis of zebrafish models of PWS resulting from genetic manipulation, and may provide informative readouts for large-scale drug screening.

Behavioral problems are a particularly challenging aspect of PWS. A variety of behavioral traits can be rapidly assessed in the zebrafish model, which has already been used to study neuropsychiatric and drug-related disorders [77,78]. In a recent study, recordings of zebrafish larvae placed in multilane plates facilitated the assessment of responses to a visual stimulus displayed on a screen. Assessed responses include avoidance behavior, thigmotaxis as measured by preference for the edge of the lane, swim speed, resting behavior, and social distance between larvae [57,79]. Optogenetic manipulation now provides direct control over behavioral circuits [75,80]. Social behavior can be further investigated by preference of adult zebrafish for the conspecific portion of a tank containing a live or virtual zebrafish, as compared with an empty sector. Fear can be measured by avoidance of the Indian leaf fish, a known zebrafish predator. Preference for the bottom of the tank, diving behavior, and preference for the dark portion of a tank, all measured by video cameras, have been used as measures of fish anxiety. Cognitive tasks can be developed similarly to mouse assays with the use of T-maze-shaped tanks. Activity monitoring can also be used to measure circadian rhythms and habituation [77]. Even food seeking and digestive physiology can be directly measured [81]. Food-seeking, tantrums, and skin-picking are all problematic PWS-associated behaviors for which no effective drug treatment has been routinely helpful. Additionally, PWS is often accompanied by mood disorders. The ability to rapidly quantify behavior in zebrafish with high sample size provides an array of additional phenotyping options for PWS models in this organism.
2.7. Strategies for Targeted Gene Manipulation

Reverse genetics in zebrafish is a promising approach to examine the complex range of phenotypes associated with PWS. One strategy is to disrupt orthologs of PWS-associated genes, and study the resulting phenotypes. As zebrafish have orthologs of the ancestral PWS-related genes, often in a much simplified context (e.g., a single MAGE gene compared with 50 human genes), zebrafish may inform the basic function of these complex genes. In addition, the contribution of the non-imprinted genes in the PWS region could be investigated. Beyond simple gene mutations, the ease of genetic manipulation makes zebrafish an ideal model for the study of gene function by knock-out, knock-in, over/mis expression, and knock-down [82].

A majority of zebrafish genes have already been mutated through the efforts of several large mutagenesis programs. The Zebrafish Mutation Project (ZMP), at the Sanger Institute identified mutant genes by Targeting Induced Local Lesions in Genomes (TILLING) libraries of ENU induced mutations. These mutant fish are available from the Zebrafish International Resource Center (ZIRC) and/or European Zebrafish Resource Center (EZRC). Another large scale genome wide screen has been done using insertional mutagenesis, and these fish are available from ZIRC [83]. In addition to these large scale genome wide collections, many labs have been generating and identifying mutations for the past twenty years, most all of which are available from the resource centers or from individual labs. Zebrafish investigators are traditionally quite open and generous.

To create new mutant lines, genome editing has been routinely accomplished using transcription activator-like effector nucleases (TALENs), and can now be achieved with greater efficiency using clustered regularly interspaced short palindromic repeats (CRISPR) technology. While TALENs require protein engineering and are time-consuming, they can be designed to specifically target any region of a gene of interest. Although somewhat more limited by sequence requirements, the CRISPR system can introduce specific mutations quickly through alteration of the sequence of the guide RNA associated with the Cas9 enzyme. This strategy facilitates the study of neurological phenotypes with a selected genetic basis [77]. For example, CRISPR-mediated knockdown of carbonic anhydrase related proteins (CARPs) that are highly expressed in the CNS has revealed a role in regulation of movement. Abnormal movement patterns were detected by video tracking of zebrafish embryos [84]. Importantly, the knock-in approach in which exogenous DNA is incorporated into the genome is also possible with CRISPR technology. This strategy has already been used to insert transgenic markers, loxP sites and small affinity tags such as HA at specific loci in zebrafish [85-87]. Additionally, single nucleotide polymorphisms have been rescued by CRISPR-mediated homology directed repair [88]. The incorporation of DNA sequences with disease-specific SNPs has been accomplished in mouse and cell culture, suggesting that this approach to the study of genetic disorders is possible in zebrafish as well.

Mutations are often associated with compensatory events that counteract the effect of the lesion [89]. Antisense morpholino oligonucleotides (MOs) do not trigger the same compensatory mechanisms, so they provide a complement to genome editing and can be used to modulate gene expression. On the other hand, MOs are subject to significant off
target effects, so MO experiments must be well-controlled and interpreted with caution [90,91]. Translation blocking MOs bind near the AUG start codon of target transcripts, thereby blocking ribosome entry and translation initiation. Alternatively, splice blocking MOs can be designed to bind to splice donor or acceptor sites to prevent normal splicing, often resulting in nonsense transcripts that are rapidly degraded in the embryo. Morpholinos enable rapid targeting of PWS-associated genes, as well as genes associated with hypothalamic development and regulation, resulting in endophenotypes relevant to PWS. Several studies have used these techniques to investigate genes implicated in PWS-like disorders demonstrating a startlingly high degree of conservation in the molecular control of brain development [27,28,30,31,92-94]. Although MOs are an important tool for investigating early brain development, they become essentially inactive by four to five days post-fertilization, making them less useful for behavioral analyses.

2.8. Approaches for Gene Discovery in Zebrafish

Zebrafish were originally selected for development as a model organism based on the ability to efficiently perform genetic analyses in this organism [95]. In the past, mutagenesis screens focused on embryonic development where they have had a major impact on our understanding of vertebrate development. More recently, mutagenesis screens have been utilized to study myriad aspects of biology. The discovery of disease genes is rapidly becoming a major focus for mutagenesis screens. Several approaches have been utilized including chemical mutagenesis, insertional mutagenesis, and protein trapping [96-102]. The standard technique for chemical mutagenesis involves exposure to ethylnitrosourea (ENU), which induces point mutations in the germline. Although highly efficient, the random nature of this technique complicates location of the mutation and identification of the mutated gene. Insertional mutagenesis involves the incorporation of exogenous DNA by injection of a retrovirus or transposon. In contrast to the ENU approach, mutated genes can be rapidly identified due to the inserted DNA, however, the mutagenesis throughput is much smaller. Similar ease of identification is possible using protein-trapping techniques, in which integration of a splice acceptor into a transcriptionally active locus results in a truncated protein and expression of the reporter construct. Throughput levels are comparable with other insertional strategies [102]. Mutagenesis has already yielded zebrafish models for a variety of CNS disorders, including Alzheimer’s disease, Dravet Syndrome, Schizophrenia and addiction [79,103,104]. A few of these models have been further utilized for drug screening, identifying promising new pharmacotherapies for their targeted disorders [58,79]. This suggests that forward genetics can also generate PWS-associated endophenotypes with an identifiable genetic basis that can be rescued in large-scale drug screens to identify therapeutic targets.

2.9. Pharmacogenomic Methods in Zebrafish

Zebrafish are increasingly being utilized for drug discovery and toxicological studies due to their small size and the high concordance of drug response between this organism and mammalian systems. In addition, dosing is straightforward as compounds are simply added to the embryo water. A major advantage of zebrafish derives from the fact that bioactive compounds can be identified based on their effects on embryonic phenotype [64,105]. Therefore, no a priori knowledge of disease genes or pathways is required for identifying
bioactive compounds. Likewise, phenotype based screens are agnostic to target organ, meaning that a drug may target a seemingly unrelated process but it will still be identified in these screens. For identifying compounds that effect hypothalamic development and function, as could be done for PWS endophenotypes, this facet of zebrafish phenotype screening would be particularly advantageous, since the neuroendocrine system is regulated by myriad, complex, poorly understood, feedback mechanisms.

A variety of chemical screen designs have been utilized over the past 15 years since the first demonstration of this approach in zebrafish. Screens have utilized numerous phenotypic endpoints including: developmental morphology, whole-mount in situ hybridization (WISH) for mRNA expression patterns, whole-mount immunohistochemistry (IHC) for protein expression patterns, survival, apoptosis, and behavior [63,64,68,69,79,105-125]. Several different compound collections have been utilized for zebrafish screening projects ranging from highly diverse chemical backbone libraries to FDA approved drug collections. For projects aiming to identify potential chemical backbones for developing new drug classes, libraries consisting of a high diversity of quality drug-like and lead-like compounds have been used, for example, Chembridge DIVERSet-EXP collection of synthetic compounds. Alternatively, if the goal is to identify genetic pathways and pharmacological targets involved in the disease process, then libraries of highly characterized compounds, such as The Library of Pharmacologically Active Compounds (LOPAC) collection of 1280 well-characterized pharmacologically active compounds, or, collections such as MicroSource spectrum, which contains 1040 US clinical trial stage drugs, 240 additional drugs marketed internationally and 800 natural products, could be used. More recently, repurposing FDA approved drugs and compounds in clinical trials has been the focus of several screens. Compound libraries for repurposing include collections such as: Enzo SCREEN-WELL® FDA approved drug library V2; the Johns Hopkins Drug Library (JHDL) consisting of 2290 drugs approved for use in humans by the FDA or international counterparts, 775 drugs at various stages in clinical trials, and 66 rare drug compounds; and the National Center for Advancing Translational Sciences (NCATS) collection of 2500 small molecular entities approved for clinical use by U.S., European Union, Japanese and Canadian authorities, along with about 1000 additional investigational compounds [64,68,105,107].

2.10. Fast Track to PWS Pharmacotherapeutics

According to the NCATS, discovering new uses for approved drugs provides the quickest possible transition from bench to bedside. The recent success of using zebrafish for phenotypic screens, particularly for repurposing FDA approved drugs presents an opportunity for fast track identification of potential pharmacotherapeutics for PWS. Perhaps the simplest approach would be to use changes in PWS-relevant hypothalamic hormone producing cells types as endpoint endophenotypes. For example, one could assay for FDA approved compounds that are capable of increasing fluorescence of oxytocin:EGFP transgenic embryos, indicating either an increase in the number of oxytocin expressing cells or an increase in oxytocin expression. The same could be done using GH, FSH or LH, all of which are deficient in PWS patients. The power of the screen would likely benefit from using several of these assays. This approach of simply screening zebrafish embryos for compounds that increase numbers or expression of normal cell types, which are relevant to
adult disease states, has recently proved to be highly successful [68,118]. A further step could be to perform these screens using zebrafish with PWS-related genetic deficits, such as sim1 mutant embryos. The endpoint would then be to rescue the endocrine defects in the mutant embryos. The power of these phenotypic screens derives from the fact that they are molecular target blind and tissue agnostic so it doesn’t matter if the reduction in oxytocin expression is a direct result of PWS pathology or if oxytocin is unrelated to PWS symptoms. If a compound increases oxytocin in zebrafish embryos, the chances are good that it will also do so in people, regardless of whether the mechanism is targeted or pleiotropic. Such bioactivity has a reasonable chance of helping to alleviate PWS symptoms. Since the screens are performed using FDA approved drugs, identified compounds could be immediately used by PWS patients.

3. Conclusions

Although the genetic basis of PWS is known, how the PWS-associated chromosomal anomalies drive neurodevelopmental deficiencies underlying this disorder is poorly understood. Mouse models have been generated that closely recapitulate PWS genetic defects, however, differences between mouse and humans appears to preclude phenocopy of this disorder between the species. On the other hand, the majority of PWS-related genes are highly conserved in mammals so a number of mouse models are providing important insight into the genetic underpinnings of PWS. Examination of potentially orthologous genes in zebrafish indicates that the imprinted PWS region has newly arisen in the mammalian lineage, within a highly conserved cluster of non-imprinted neural related genes. Thus, zebrafish models of PWS genes would focus on the ancestral precursors of the imprinted genes or on the non-imprinted genes. In contrast, the genes and pathways controlling development, which are presumably disrupted in PWS, are highly conserved and thus can be productively modeled in zebrafish. This is particularly true in the hypothalamus where neuroendocrine cell types that are effected in PWS are highly conserved. Therefore, forward and reverse genetic approaches in zebrafish accompanied by phenotypic analysis technologies can be used to identify drug targets and lead to a deeper understanding of the pathways underlying PWS-associated phenotypes, complimenting ongoing studies in mice. An important advantage of zebrafish is that potential PWS models can be utilized for high-throughput drug screening, a feature not found in any other vertebrate model system. Given our current understanding of the molecular genetic underpinnings of PWS and the long lead times for drug development, a phenotypic screening program for FDA approved drugs in zebrafish may represent the fastest path to identifying potential curative therapies.

Acknowledgments

We thank Kathrine E. Schertz for initiating the literature searches and Chamille J. Lescott for critical edits. This work was supported in part by NIH/NCI grant CA51008.

References

1. Angulo MA, Butler MG, Cataletto ME. Prader-Willi syndrome: A review of clinical, genetic, and endocrine findings. J. Endocrinol. Invest. 2015; 38:1249–1263. [CrossRef] [PubMed]. [PubMed: 26062517]

Diseases. Author manuscript; available in PMC 2016 November 15.
2. Cassidy SB, Schwartz S, Miller JL, Driscoll DJ. Prader-Willi syndrome. Genet. Med. 2012; 14:10–26. [CrossRef] [PubMed]. [PubMed: 22237428]

3. Emerick JE, Vogt KS. Endocrine manifestations and management of Prader-Willi syndrome. Int. J. Pediatr. Endocrinol. 2013; 1:14. [CrossRef] [PubMed].

4. Benarroch F, Hirsch HJ, Genstil L, Landau YE, Gross-Tsur V. Prader-Willi syndrome: Medical prevention and behavioral challenges. Child. Adolesc. Psychiatr. Clin. N. Am. 2007; 16:695–708. [CrossRef] [PubMed]. [PubMed: 17562587]

5. Bridges N. What is the value of growth hormone therapy in Prader willi syndrome? Arch. Dis. Child. 2014; 99:166–170. [CrossRef] [PubMed]. [PubMed: 24162007]

6. Goldstone AP. Prader-Willi syndrome: Advances in genetics, pathophysiology and treatment. Trends Endocrinol. MeTable. 2004; 15:12–20. [CrossRef].

7. Nixon GM, Brouillette RT. Sleep and breathing in Prader-Willi syndrome. Pediatr. Pulmonol. 2002; 34:209–217. [CrossRef] [PubMed]. [PubMed: 12203850]

8. Lohr H, Hammerschmidt M. Zebrafish in endocrine systems: Recent advances and implications for human disease. Annu. Rev. Physiol. 2011; 73:183–211. [CrossRef] [PubMed]. [PubMed: 21314433]

9. Pickart MA, Klee EW. Zebrafish approaches enhance the translational research tackle box. Transl. Res. 2014; 163:65–78. [CrossRef] [PubMed]. [PubMed: 24269745]

10. Howe K, Clark MD, Torroja CF, Torrance J, Berthelot C, Muffato M, Collins JE, Humphray S, McLaren K, Matthews L, et al. The zebrafish reference genome sequence and its relationship to the human genome. Nature. 2013; 496:498–503. [CrossRef] [PubMed]. [PubMed: 23594743]

11. Zhang YJ, Yang JH, Shi QS, Zheng LL, Liu J, Zhou H, Zhang H, Qu LH. Rapid birth-and-death evolution of imprinted snornas in the Prader-Willi syndrome locus: Implications for neural development in euarchontoglires. PLoS ONE. 2014; 9:e100329. [CrossRef] [PubMed]. [PubMed: 24945811]

12. Dunzinger U, Haaf T, Zechnner U. Conserved synteny of mammalian imprinted genes in chicken, frog, and fish genomes. Cyto-genet. Genome Res. 2007; 117:78–85. [CrossRef] [PubMed]. [PubMed: 17675847]

13. Bohne A, Darras A, D’Cotta H, Baroilier JF, Galiana-Arnoux D, Wolff JN. The vertebrate makorin ubiquitin ligase gene family has been shaped by large-scale duplication and retroposition from an ancestral gonad-specific, maternal-effect gene. BMC Genomics. 2010; 11:721. [CrossRef] [PubMed]. [PubMed: 21172006]

14. Catchen JM, Conery JS, Postlethwait JH. Automated identification of conserved synteny after whole-genome duplication. Genome Res. 2009; 19:1497–1505. [CrossRef] [PubMed]. [PubMed: 19465509]

15. Bischof JM, Ekker M, Wevrick R. A MAGE/NDN-like gene in zebrafish. Dev. Dyn. 2003; 228:475–479. [CrossRef] [PubMed]. [PubMed: 14579385]

16. Bervini S, Herzog H. Mouse models of Prader-Willi syndrome: A systematic review. Front. Neuroendocrinol. 2013; 34:107–119. [CrossRef] [PubMed]. [PubMed: 23391702]

17. Neumann LC, Feiner N, Meyer A, Buiting K, Horsthemke B. The imprinted npapl gene in the Prader-Willi syndrome region belongs to a POM121-related family of retrogenes. Genome Biol. Evol. 2014; 6:344–351. [CrossRef] [PubMed]. [PubMed: 24482533]

18. Cavaille J, Buiting K, Kiefmann M, Lalande M, Brannan CI, Horsthemke B, Bachelier JP, Brosius J, Huttenhofer A. Identification of brain-specific and imprinted small nucleolar RNA genes exhibiting an unusual genomic organization. Proc. Natl. Acad. Sci. USA. 2000; 97:14311–14316. [CrossRef] [PubMed]. [PubMed: 1106375]

19. De los Santos T, Schweizer J, Rees CA, Francke U. Small evolutionarily conserved RNA, resembling C/D box small nucleolar RNA, is transcribed from PWCR1, a novel imprinted gene in the Prader-Willi deletion region, which is highly expressed in brain. Am. J. Hum. Genet. 2000; 67:1067–1082. [CrossRef] [PubMed]. [PubMed: 11007541]

20. El Khattabi L, Guimiot F, Pipiras E, Andrieux J, Baumann C, Bouquillon S, Delezoide AL, Delobel B, Demurger F, Dessuant H, et al. Incomplete penetrance and phenotypic variability of 6q16 deletions including SIM1. Eur. J. Hum. Genet. 2015; 23:1010–1018. [CrossRef] [PubMed]. [PubMed: 25351778]
21. Bonnefond A, Raimondo A, Stutzmann F, Ghoussaini M, Ramachandrappa S, Bersten DC, Durand E, Vatin V, Balkau B, Lantieri O, et al. Loss-of-function mutations in SIM1 contribute to obesity and Prader-Willi-like features. J. Clin. Invest. 2013; 123:3037–3041. [CrossRef] [PubMed]. [PubMed: 23778136]

22. Izumi K, Housam R, Kapadia C, Stallings VA, Medne L, Shaikh TH, Kublaoui BM, Zackai EH, Grimbarg A. Endocrine phenotype of 6q16.1-q21 deletion involving SIM1 and Prader-Willi syndrome-like features. Am. J. Med. Genet. A. Part. A. 2013; 161A:3137–3143. [CrossRef] [PubMed].

23. Tolson KP, Gemelli T, Gautron L, Elmquist JK, Zinn AR, Kublaoui BM. Postnatal Sim1 deficiency causes hyperphagic obesity and reduced Mc4r and Oxytocin expression. J. Neurosci. 2010; 30:3803–3812. [CrossRef] [PubMed]. [PubMed: 20220015]

24. Tolson KP, Gemelli T, Meyer D, Yazdani U, Kozlitina J, Zinn AR. Inducible neuronal inactivation of SIM1 in adult mice causes hyperphagic obesity. Endocrinology. 2014; 155:2436–2444. [CrossRef] [PubMed]. [PubMed: 24773343]

25. Heymsfield SB, Avena NM, Baier L, Brantley P, Burnett LC, Butler MG, Driscoll DJ, Egli D, Elmquist J, et al. Hyperphagia: Current concepts and future directions proceedings of the 2nd international conference on hyperphagia. Obesity. 2014; 22(Suppl. S1):S1–S17. [CrossRef] [PubMed].

26. Blevins JE, Ho JM. Role of oxytocin signaling in the regulation of body weight. Rev. Endocr. Metab. Disord. 2013; 14:311–329. [CrossRef] [PubMed]. [PubMed: 24065622]

27. Kasher PR, Schertz KE, Thomas M, Jackson A, Annunziata S, Ballesta-Martinez MJ, Campeau PM, Clayton PE, Eaton JL, Granata T, et al. Small 6q16.1 deletions encompassing POU3F2 cause susceptibility to obesity and variable developmental delay with intellectual disability. Am. J. Hum. Genet. 2016; 98:363–372. [CrossRef] [PubMed]. [PubMed: 26833329]

28. Eaton JL, Glasgow E. The zebrafish bhlh pas transcriptional regulator, single-minded 1 (SIM1), is required for isotocin cell development. Dev. Dyn. 2006; 235:2071–2082. [CrossRef] [PubMed]. [PubMed: 16691572]

29. Unger JL, Glasgow E. Expression of isotocin-neurophysin mrna in developing zebratish. Gene Expr. Patterns. 2003; 3:105–108. [CrossRef]. [PubMed: 12609611]

30. Eaton JL, Holmqvist B, Glasgow E. Ontogeny of vasotocin-expressing cells in zebrafish: Selective requirement for the transcriptional regulators orthopedia and single-minded 1 in the preoptic area. Dev. Dyn. 2008; 237:995–1005. [CrossRef] [PubMed]. [PubMed: 18330923]

31. Lohr H, Ryu S, Driever W. Zebrafish diencephalic A11-related dopaminergic neurons share a conserved transcriptional network with neuroendocrine cell lineages. Development. 2009; 136:1007–1017. [CrossRef] [PubMed]. [PubMed: 19234064]

32. Michaud JL, DeRossi C, May NR, Holdener BC, Fan C-M. ARNT2 acts as the dimerization partner of SIM1 for the development of the hypothalamus. Mech. Dev. 2000; 90:253–261. [CrossRef] [PubMed]. [PubMed: 10640708]

33. Michaud JL, Rosenquist T, May NR, Fan CM. Development of neuroendocrine lineages requires the bHLH-PAS transcription factor SIM1. Genes Dev. 1998; 12:3264–3275. [CrossRef] [PubMed]. [PubMed: 9784500]

34. Nakai S, Kawano H, Yudate T, Nishi M, Kuno J, Nagata K, Jishage K, Hamada H, Fujii H, Kawamura K. The POU domain transcription factor Brn-2 is required for the determination of specific neuronal lineages in the hypothalamus of the mouse. Genes Dev. 1995; 9:3109–3121. [CrossRef] [PubMed]. [PubMed: 8543155]

35. Schonemann MD, Ryan AK, McEvilly RJ, O’Connell SM, Arias CA, Kalla KA, Li P, Sawchenko PE, Rosenfeld MG. Development and survival of the endocrine hypothalamus and posterior pituitary gland requires the neuronal POU domain factor Brn-2. Genes Dev. 1995; 9:3122–3135. [CrossRef] [PubMed]. [PubMed: 8543156]

36. Cattanach BM, Barr JA, Evans EP, Burtenshaw M, Beechey CV, Leff SE, Brannan CI, Copeland NG, Jenkins NA, Jones JA. candidate mouse model for Prader-Willi syndrome which shows an absence of snrpn expression. Nat. Genet. 1992; 2:270–274. [CrossRef] [PubMed]. [PubMed: 1303278]
37. Gabriel JM, Merchant M, Ohta T, Ji Y, Caldwell RG, Ramsey MJ, Tucker JD, Longnecker R, Nicholls RD. A transgene insertion creating a heritable chromosome deletion mouse model of Prader-Willi and angelman syndromes. Proc. Natl. Acad. Sci. USA. 1999; 96:9258–9263. [CrossRef] [PubMed]. [PubMed: 10430930]

38. Dubose AJ, Smith EY, Yang TP, Johnstone KA, Resnick JL. A new deletion refines the boundaries of the murine Prader-Willi syndrome imprinting center. Hum. Mol. Gen. 2011; 20:3461–3466. [CrossRef] [PubMed]. [PubMed: 21659337]

39. Bressler J, Tsai TF, Wu MY, Tsai SE, Ramirez MA, Armstrong D, Beaudet AL. The snrpn promoter is not required for genomic imprinting of the Prader-Willi/angelman domain in mice. Nat. Genet. 2001; 28:232–240. [CrossRef] [PubMed]. [PubMed: 11431693]

40. Tsai TF, Jiang YH, Bressler J, Armstrong D, Beaudet AL. Paternal deletion from Snrpn to Ube3a in the mouse causes hypotonia, growth retardation and partial lethality and provides evidence for a gene contributing to Prader-Willi syndrome. Hum. Mol. Gen. 1999; 8:1357–1364. [CrossRef] [PubMed]. [PubMed: 10400982]

41. Yang T, Adamson TE, Resnick JL, Jeff S, Wervick R, Franke U, Jenkins NA, Copeland NG, Brennan CI. A mouse model for Prader-Willi syndrome imprinting-centre mutations. Nat. Genet. 1998; 19:25–31. [CrossRef] [PubMed]. [PubMed: 9590284]

42. Kozlov SV, Bogenpohl JW, Howell MP, Wervick R, Panda S, Hogenesch JB, Muglia LJ, van Gelder RN, Herzog ED, Stewart CL. The imprinted gene Magel2 regulates normal circadian output. Nat. Genet. 2007; 39:1266–1272. [CrossRef] [PubMed]. [PubMed: 17893678]

43. Muscatelli F, Abrous DN, Massacrier A, Boccaccio I, le Moal M, Cau P, Cremer H. Disruption of the mouse necdn gene results in hypothalamic and behavioral alterations reminiscent of the human Prader-Willi syndrome. Hum. Mol. Gen. 2000; 9:3101–3110. [CrossRef] [PubMed]. [PubMed: 11115855]

44. Mercer RE, Kwolek EM, Bischof JM, van Eede M, Henkelman RM, Wervick R. Regionally reduced brain volume, altered serotonin neurochemistry, and abnormal behavior in mice null for the circadian rhythm output gene Magel2. Am. J. Med. Genet. B. 2009; 150B:1085–1099. [CrossRef] [PubMed].

45. Ding F, Li HH, Zhang S, Solomon NM, Camper SA, Cohen P, Francke U. SnoRNA Snord116 (Pwcr1/MBII-85) deletion causes growth deficiency and hyperphagia in mice. PLoS ONE. 2008; 3:e1709. [CrossRef] [PubMed]. [PubMed: 18320030]

46. Bischof JM, Stewart CL, Wervick R. Inactivation of the mouse Magel2 gene results in growth abnormalities similar to Prader-Willi syndrome. Hum. Mol. Gen. 2007; 16:2713–2719. [CrossRef] [PubMed]. [PubMed: 17728320]

47. Aycan Z, Bas VN. Prader-Willi syndrome and growth hormone deficiency. J. Clin. Res. Pediatr. Endocrinol. 2014; 6:62–67. [CrossRef] [PubMed]. [PubMed: 24932597]

48. Biran J, Tahor M, Wircer E, Levkowitz G. Role of developmental factors in hypothalamic function. Front. Neuroanat. 2015; 9:47. [CrossRef] [PubMed]. [PubMed: 25954163]

49. Markakis EA. Development of the neuroendocrine hypothalamus. Front. Neuroendocrinol. 2002; 23:257–291. [CrossRef] [PubMed]. [PubMed: 12127306]

50. Shubin, N. Your Inner Fish: A Journey into the 3.5-Billion-Year History of the Human Body. 1st ed.. Vintage Books; New York, NY, USA: 2009. p. 237

51. Linden, DJ. The Accidental Mind. Belknap Press of Harvard University Press; Cambridge, MA, USA: 2007. p. 276

52. Stewart AM, Kaluuff AV. Developing better and more valid animal models of brain disorders. Behav. Brain Res. 2015; 276:28–31. [CrossRef] [PubMed]. [PubMed: 24384129]

53. Herget U, Ryu S. Coexpression analysis of nine neuropeptides in the neurosecretory preoptic area of larval zebrafish. Front. Neuroanat. 2015; 9:2. [CrossRef] [PubMed]. [PubMed: 25729355]

54. Herget U, Wolf A, Wullimann MF, Ryu S. Molecular neuroanatomy and chemoarchitecture of the neurosecretory preoptic-hypothalamic area in zebrafish larvae. J. Comp. Neurol. 2014; 522:1542–1564. [CrossRef] [PubMed]. [PubMed: 24127437]

55. Woods IG, Schoppik D, Shi VJ, Zimmerman S, Coleman HA, Greenwood J, Soucy ER, Schier AF. Neuropeptidergic signaling partitions arousal behaviors in zebrafish. J. Neurosci. 2014; 34:3142–3160. [CrossRef] [PubMed]. [PubMed: 24573274]
56. Bruni G, Lakhani P, Kokel D. Discovering novel neuroactive drugs through high-throughput behavior-based chemical screening in the zebrafish. Front. Pharmacol. 2014; 5:153. [CrossRef] [PubMed: 25104936]

57. Clift D, Richendrfer H, Thorn RJ, Colwill RM, Creton R. High-throughput analysis of behavior in zebrafish larvae: Effects of feeding. Zebrafish. 2014; 11:455–461. [CrossRef] [PubMed: 25153037]

58. Cousin MA, Ebbert JO, Winamaki AR, Urban MD, Argue DP, Ekker SC, Klee EW. Larval zebrafish model for FDA-approved drug repositioning for tobacco dependence treatment. PLoS ONE. 2014; 9:e90467. [CrossRef] [PubMed: 24658307]

59. Cross LM, Cook MA, Lin S, Chen JN, Rubinstein AL. Rapid analysis of angiogenesis drugs in a live fluorescent zebrafish assay. Arterioscler. Thromb. Vasc. Biol. 2003; 23:911–912. [CrossRef] [PubMed: 25104936]

60. Das BC, McCartin K, Liu TC, Peterson RT, Evans T. A forward chemical screen in zebrafish identifies a retinoic acid derivative with receptor specificity. PLoS ONE. 2010; 5:e10004. [CrossRef] [PubMed: 20368991]

61. Haesemeyer M, Schier AF. The study of psychiatric disease genes and drugs in zebrafish. Curr. Opin. Neurobiol. 2015; 30:122–130. [CrossRef] [PubMed: 25523356]

62. Kaufman CK, White RM, Zon L. Chemical genetic screening in the zebrafish embryo. Nat. Protoc. 2009; 4:1422–1432. [CrossRef] [PubMed: 19745824]

63. Le X, Pugach EK, Hettmer S, Storer NY, Liu J, Wills AA, DiBiase A, Chen EY, Ignatius MS, Poss KD, et al. A novel chemical screening strategy in zebrafish identifies common pathways in embryogenesis and rhabdomyosarcoma development. Development. 2013; 140:2354–2364. [CrossRef] [PubMed: 23615277]

64. MacRae CA, Peterson RT. Zebrafish as tools for drug discovery. Nat. Rev. Drug Discov. 2015; 14:721–731. [CrossRef] [PubMed: 26361349]

65. McCammon JM, Sive H. Challenges in understanding psychiatric disorders and developing therapeutics: A role for zebrafish. Dis. Model. Mech. 2015; 8:647–656. [CrossRef] [PubMed: 26092527]

66. Pardo-Martin C, Allalou A, Medina J, Eimon PM, Wahlby C, Fatih Yanik M. High-throughput hyperdimensional vertebrate phenotyping. Nat. Commun. 2013; 4:1467. [CrossRef] [PubMed: 23403568]

67. Phillips JB, Westerfield M. Zebrafish models in translational research: Tipping the scales toward advancements in human health. Dis. Model. Mech. 2014; 7:739–743. [CrossRef] [PubMed: 24973743]

68. Wang G, Rajpurohit SK, Delaspre F, Walker SL, White DT, Ceasrine A, Kuruvilla R, Li RJ, Shim JS, Liu JO, et al. First quantitative high-throughput screen in zebrafish identifies novel pathways for increasing pancreatic -cell mass. eLife. 2015; 4 [CrossRef] [PubMed: 22545806]

69. Weger BD, Weger M, Nusser M, Brenner-Weiss G, Dickmeis T. A chemical screening system for glucocorticoid stress hormone signaling in an intact vertebrate. ACS Chem. Biol. 2012; 7:1178–1183. [CrossRef] [PubMed: 22545806]

70. Coffey CM, Solleveld PA, Fang J, Roberts AK, Hong SK, Dawid IB, Laverriere CE, Glasgow E. Novel oxytocin gene expression in the hindbrain is induced by alcohol exposure: Transgenic zebrafish enable visualization of sensitive neurons. PLoS ONE. 2013; 8:e53991. [CrossRef] [PubMed: 23342055]

71. Liu NA, Huang H, Yang Z, Herzog W, Hammerschmidt M, Lin S, Melmed S. Pituitary corticotroph ontogeny and regulation in transgenic zebrafish. Mol. Endocrinol. 2003; 17:959–966. [CrossRef] [PubMed: 12576489]

72. Sun L, Xu W, He J, Yin Z. In vivo alternative assessment of the chemicals that interfere with anterior pituitary POMC expression and interrenal steroidogenesis in POMC: EGFP transgenic zebrafish. Toxicol. Appl. Pharmacol. 2010; 248:217–225. [CrossRef] [PubMed: 20732339]

73. Golan M, Zelinger E, Zohar Y, Levavi-Sivan B. Architecture of GnRH-gonadotrope-vasculature reveals a dual mode of gonadotropin regulation in fish. Endocrinology. 2015; 156:4163–4173. [CrossRef] [PubMed: 26261873]
74. Liu NA, Liu Q, Wawrowsky K, Yang Z, Lin S, Melmed S. Prolactin receptor signaling mediates the osmotic response of embryonic zebrafish lactotrophs. Mol. Endocrinol. 2006; 20:871–880. [CrossRef] [PubMed]. [PubMed: 16339273]

75. Singh C, Oikonomou G, Prober DA. Norepinephrine is required to promote wakefulness and for hypocretin-induced arousal in zebrafish. eLife. 2015; 4 [CrossRef] [PubMed].

76. Meguro S, Hasumura T, Hase T. Body fat accumulation in zebrafish is induced by a diet rich in fat and reduced by supplementation with green tea extract. PLoS ONE. 2015; 10:e0120142. [CrossRef] [PubMed]. [PubMed: 25785691]

77. Kalueff AV, Stewart AM, Gerlai R. Zebrafish as an emerging model for studying complex brain disorders. Trends Pharmacol. Sci. 2014; 35:63–75. [CrossRef] [PubMed]. [PubMed: 24412421]

78. Egan RJ, Bergner CL, Hart PC, Cachat JM, Canavello PR, Elegante MF, Elkhayat SI, Bartels BK, Tien AK, Tien DH, et al. Understanding behavioral and physiological phenotypes of stress and anxiety in zebrafish. Behav. Brain Res. 2009; 205:38–44. [CrossRef] [PubMed].

79. Baraban SC, Dinday MT, Hortopan GA. Drug screening in scn1a zebrafish mutant identifies clemizole as a potential dravet syndrome treatment. Nat. Commun. 2013; 4:2410. [CrossRef] [PubMed]. [PubMed: 24002024]

80. De Marco RJ, Groneberg AH, Yeh CM, Castillo Ramirez LA, Ryu S. Optogenetic elevation of endogenous glucocorticoid level in larval zebrafish. Front. in neural circuits. 2013; 7:82. [CrossRef] [PubMed].

81. Jordi J, Guggiana-Niño D, Soucy E, Song EY, Wee CL, Engert F. A high-throughput assay for quantifying appetite and digestive dynamics. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2015; 309:345–357. [CrossRef] [PubMed].

82. Lawson ND, Wolfe SA. Forward and reverse genetic approaches for the analysis of vertebrate development in the zebrafish. Dev. Cell. 2011; 21:48–64. [CrossRef] [PubMed]. [PubMed: 21763608]

83. Varshney GK, Lu J, Gildea DE, Huang H, Pei W, Yang Z, Huang SC, Schoenfeld D, Pho NH, Casero D, et al. A large-scale zebrafish gene knockout resource for the genome-wide study of gene function. Genome Res. 2013; 23:727–735. [CrossRef] [PubMed]. [PubMed: 23382537]

84. Aspatwar A, Tolvanen ME, Ojanen MJ, Barker HR, Saralahti AK, Bauerlein CA, Orutay C, Pan P, Kuuslahti M, Parikka M, et al. Inactivation of cal1b and ca10b genes leads to abnormal embryonic development and alters movement pattern in zebrafish. PLoS ONE. 2015; 10:e0134263. [CrossRef] [PubMed]. [PubMed: 26218428]

85. Kimura Y, Hisano Y, Kawahara A, Higashijima S. Efficient generation of knock-in transgenic zebrafish carrying reporter/driver genes by CRISPR/Cas9-mediated genome engineering. Sci. Rep. 2014; 4:6545. [CrossRef] [PubMed]. [PubMed: 2293390]

86. Chang N, Sun C, Gao L, Zhu D, Xu X, Zhu X, Xiong JW, Xi JJ. Genome editing with RNA-guided Cas9 nuclease in zebrafish embryos. Cell Res. 2013; 23:465–472. [CrossRef] [PubMed]. [PubMed: 23528705]

87. Hruscha A, Krawitz P, Rechenberg A, Heinrich V, Hecht J, Haass C, Schmid B. Efficient CRISPR/Cas9 genome editing with low off-target effects in zebrafish. Development. 2013; 140:4982–4987. [CrossRef] [PubMed]. [PubMed: 24257628]

88. Irion U, Krauss J, Nusslein-Volhard C. Precise and efficient genome editing in zebrafish using the CRISPR/Cas9 system. Development. 2014; 141:4827–4830. [CrossRef] [PubMed]. [PubMed: 25411213]

89. Rossi A, Kontarakis Z, Gerri C, Nolte H, Holper S, Kruger M, Stainier DY. Genetic compensation induced by deleterious mutations but not gene knockdowns. Nature. 2015; 524:230–233. [CrossRef] [PubMed]. [PubMed: 26168398]

90. Kok FO, Shin M, Ni CW, Gupta A, Grosse AS, van Impel A, Kirchmaier BC, Peterson-Maduro J, Kourkoulis G, Male I, et al. Reverse genetic screening reveals poor correlation between morpholino-induced and mutant phenotypes in zebrafish. Dev. Cell. 2015; 32:97–108. [CrossRef] [PubMed]. [PubMed: 25533206]

91. Eisen JS, Smith JC. Controlling morpholino experiments: Don’t stop making antisense. Development. 2008; 135:1735–1743. [CrossRef] [PubMed]. [PubMed: 18403413]
92. Eaton JL, Glasgow E. Zebrafish orthopedia (otp) is required for isotocin cell development. Dev. Genes Evol. 2007; 217:149–158. [CrossRef] [PubMed]. [PubMed: 17180684]
93. Catalina-Rodriguez O, Kolukula VK, Tomita Y, Preet A, Palmieri F, Wellstein A, Byers S, Giaccia AJ, Glasgow E, Albanese C, et al. The mitochondrial citrate transporter, CIC, is essential for mitochondrial homeostasis. Oncotarget. 2012; 3:1220–1235. [CrossRef] [PubMed]. [PubMed: 23100451]
94. Blechman J, Borodovsky N, Eisenberg M, Nabel-Rosen H, Grimm J, Levkowitz G. Specification of hypothalamic neurons by dual regulation of the homeodomain protein orthopedia. Development. 2007; 134:4417–4426. [CrossRef] [PubMed]. [PubMed: 17714032]
95. Streisinger G, Walker C, Dower N, Knauber D, Singer F. Production of clones of homozygous diploid zebra fish (Brachydanio rerio). Nature. 1981; 291:293–296. [CrossRef] [PubMed]. [PubMed: 7248006]
96. Haffter P, Granato M, Brand M, Mullins MC, Hammerschmidt M, Kane DA, Odenthal J, van Eeden FJ, Jiang YJ, Heisenberg CP, et al. The identification of genes with unique and essential functions in the development of the zebrafish, Danio rerio. Development. 1996; 123:1–36. [PubMed]. [PubMed: 9007226]
97. Amsterdam A, Burgess S, Golling G, Chen W, Sun Z, Townsend K, Farrington S, Haldi M, Hopkins N. A large-scale insertional mutagenesis screen in zebrafish. Genes Dev. 1999; 13:2713–2724. [CrossRef] [PubMed]. [PubMed: 10541557]
98. Wang D, Jao LE, Zheng N, Dolan K, Ivey J, Zonies S, Wu X, Wu K, Yang H, Meng Q, et al. Efficient genome-wide mutagenesis of zebrafish genes by retroviral insertions. Proc. Natl. Acad. Sci. USA. 2007; 104:12428–12433. [CrossRef] [PubMed]. [PubMed: 17640903]
99. Petzold AM, Balciunas D, Sivasubbu S, Amsterdam A, Ekker SC. Nicotine response genetics in the zebrafish. Proc. Natl. Acad. Sci. USA. 2009; 106:18662–18667. [CrossRef] [PubMed]. [PubMed: 19858493]
100. Rennekamp AJ, Peterson RT. 15 Years of zebrafish chemical screening. Curr. Opin. Chem. Biol. 2015; 24:58–70. [CrossRef] [PubMed]. [PubMed: 25461724]
101. Wyatt C, Bartoszek EM, Yaksi E. Methods for studying the zebrafish brain: Past, present and future. Eur. J. Neurosci. 2015; 42:1746–1763. [CrossRef] [PubMed]. [PubMed: 25900995]
102. Metelo AM, Noonan HR, Li X, Jin Y, Baker R, Kamentsky L, Zhang Y, van Rooijen E, Carpenter AE, et al. Pharmacological HIF2 inhibition improves VHL disease-associated phenotypes in zebrafish model. J. Clin. Invest. 2015; 125:1987–1997. [CrossRef] [PubMed]. [PubMed: 25869695]
103. Wittmann C, Reischl M, Shah AH, Kronfuss E, Mikut R, Liebel U, Grabher C. A zebrafish drug-repurposing screen reveals sGC-dependent and sGC-independent pro-inflammatory activities of nitric oxide. PLoS ONE. 2015; 10:e0137286. [CrossRef] [PubMed]. [PubMed: 26444552]
104. Li P, Lahvic JL, Binder V, Pugach ED, Tamplin OJ, Panighray D, Bowman TV, Barrett FG, Hefnner GC, et al. Epoxycisatrienoic acids enhance embryonic haematopoiesis and adult marrow engraftment. Nature. 2015; 523:468–471. [CrossRef] [PubMed]. [PubMed: 26201599]
105. Evasion KJ, Francisco MT, Juric V, Balakrishnan S, Pazmino MDPL, Gordan JD, Kakar S, Spitsbergen J, Goga A, Stainier DY. Identification of chemical inhibitors of beta-catenin-driven liver tumorigenesis in zebrafish. PLoS Genet. 2015; 11:e1005305. [CrossRef] [PubMed]. [PubMed: 26134322]

Diseases. Author manuscript; available in PMC 2016 November 15.
110. Gallardo VE, Varshney GK, Lee M, Bupp S, Xu L, Shinn P, Crawford NP, Inglese J, Burgess SM. Phenotype-driven chemical screening in zebrafish for compounds that inhibit collective cell migration identifies multiple pathways potentially involved in metastatic invasion. Dis. Model. Mech. 2015; 8:565–576. [CrossRef] [PubMed]. [PubMed: 25810455]

111. Williams CH, Hempel JE, Hao J, Frist AY, Williams MM, Fleming JT, Sulikowski GA, Cooper MK, Chiang C, Hong CC. An in vivo chemical genetic screen identifies phosphodiesterase 4 as a pharmacological target for hedgehog signaling inhibition. Cell Rep. 2015; 11:43–50. [CrossRef] [PubMed]. [PubMed: 25818300]

112. Nath AK, Ryu JH, Jin YN, Roberts LD, Dejam A, Gerszten RE, Peterson RT. PTPMT1 inhibition lowers glucose through succinate dehydrogenase phosphorylation. Cell Rep. 2015; 10:694–701. [CrossRef] [PubMed].

113. Tsuji N, Ninov N, Delawary M, Osman S, Roh AS, Gut P, Stainier DY. Whole organism high content screening identifies stimulators of pancreatic -cell proliferation. PLoS ONE. 2014; 9:e104112. [PubMed: 25117518]

114. Nishiya N, Oku Y, Kumagai Y, Sato Y, Yamaguchi E, Sasaki A, Shoji M, Ohnishi Y, Okamoto H, Uehara Y. A zebrafish chemical suppressor screening identifies small molecule inhibitors of the Wnt/-catenin pathway. Chem. Biol. 2014; 21:530–540. [CrossRef] [PubMed]. [PubMed: 24684907]

115. Kong Y, Grimaldi M, Curtin E, Dougherty M, Kaufman C, White RM, Zon LI, Liao EC. Neural crest development and craniofacial morphogenesis is coordinated by nitric oxide and histone acetylation. Chem. Biol. 2014; 21:488–501. [CrossRef] [PubMed]. [PubMed: 24684905]

116. Gebruers E, Cordero-Maldonado ML, Gray AI, Clements C, Harvey AL, Edrada-Ebel R, de Witte PA, Crawford AD, Esquerra CV. A phenotypic screen in zebrafish identifies a novel small-molecule inducer of ectopic tail formation suggestive of alterations in non-canonical Wnt/PCP signaling. PLoS ONE. 2013; 8:e83293. [CrossRef] [PubMed]. [PubMed: 24349481]

117. Hao J, Ao A, Zhou L, Murphy CK, Frist AY, Keel JJ, Thorne CA, Kim K, Lee E, Hong CC. Selective small molecule targeting -catenin function discovered by in vivo chemical genetic screen. Cell Rep. 2013; 4:898–904. [CrossRef] [PubMed]. [PubMed: 24012757]

118. Ridges S, Heaton WL, Joshi D, Choi H, Eiring A, Batchelor L, Choudhry P, Manos EJ, Sofla H, Sanati A, et al. Zebrafish screen identifies novel compound with selective toxicity against leukemia. Blood. 2012; 119:5621–5631. [CrossRef] [PubMed]. [PubMed: 22490804]

119. Gutierrez A, Pan L, Groen RW, Baleydier F, Kentsis A, Marineau J, Grebliunaite R, Kozakewich E, Reed C, Pflumio F, et al. Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia. J. Clin. Invest. 2014; 124:644–655. [CrossRef] [PubMed]. [PubMed: 24401270]

120. Kokel D, Cheung CY, Mills R, Coutinho-Budd J, Huang L, Setola V, Sprague J, Jin S, Jin YN, Huang XP, et al. Photochemical activation of TRPA1 channels in neurons and animals. Nat. Chem. Biol. 2013; 9:257–263. [CrossRef] [PubMed]. [PubMed: 23396078]

121. Dinday MT, Baraban SC. Large-scale phenotype-based antiepileptic drug screening in a zebrafish model of dravet syndrome(1,2,3). eNeuro. 2015; 2 [CrossRef] [PubMed].

122. Gut P, Baeza-Raja B, Andersson O, Hasenkamp L, Hsiao J, Hesselson D, Akassoglou K, Verdin E, Hirshey MD, Stainier DY. Whole-organism screening for gluconeogenesis identifies activators of fasting metabolism. Nat. Chem. Biol. 2013; 9:97–104. [CrossRef] [PubMed]. [PubMed: 23201900]

123. Asimaki A, Kapoor S, Plovie E, Karin Arndt A, Adams E, Liu Z, James CA, Judge DP, Calkins H, Churko J, et al. Identification of a new modulator of the intercalated disc in a zebrafish model of arrhythmicogenic cardiomyopathy. Sci. Transl. Med. 2014; 6 [CrossRef] [PubMed].

124. Bulut G, Hong SH, Chen K, Beauchamp EM, Rahim S, Kosturko GW, Glasgow E, Dakshnamurthy S, Lee HS, Daar I, et al. Small molecule inhibitors of ezrin inhibit the invasive phenotype of osteosarcoma cells. Oncogene. 2012; 31:269–281. [CrossRef] [PubMed]. [PubMed: 21706056]

125. Rihel J, Prober DA, Arvanites A, Lam K, Zimmerman S, Jang S, Haggarty SJ, Kokel D, Rubin LL, Peterson RT, et al. Zebrafish behavioral profiling links drugs to biological targets and rest/wake regulation. Science. 2010; 327:348–351. [CrossRef] [PubMed]. [PubMed: 20075256]
Figure 1.
Overview of approaches for investigating PWS using zebrafish. (I) Genes and molecular pathways can be genetically or pharmacologically perturbed. (II) The effect of perturbations can be evaluated using a variety of phenotypic analyses. PWS endophenotypes may then be utilized as disease models and subjected to drug screening to identify potential pharmacotherapeutics.
### Table 1

Medical characteristics and treatment options.

| Medical Symptom                     | Age of Onset          | Treatment Options                                                                 |
|-------------------------------------|-----------------------|-----------------------------------------------------------------------------------|
| hypotonia and feeding difficulties  | 0–9 months            | feeding assistance, nasogastric tubes                                              |
| hyperphagia                         | 4.5–8 years           | behavioral therapy                                                                |
| short stature                       | puberty               | GH therapy, allows patients to reach full adult height                              |
| hypoplastic genitalia               | birth                 | hormonal replacement therapy                                                       |
| dysmorphic features                 | birth                 | none                                                                              |
| sleep-disordered breathing          | childhood to adolescence (Nixon and Brouillette) | adenotonsillectomy, nocturnal ventilation, weight control, and behavioral interventions |
| cognitive disability                | childhood             | none                                                                              |
| skin picking and obsessive behavior | 5 years               | behavioral therapy                                                                |
| oppositional behavior and tantrums  | 5 years               | behavioral therapy and psychiatric drugs                                           |
Table 2

Mouse and zebrafish PWS-related genes.

| Human   | Mouse   | % aa | Zebrafish | % aa | Chr. |
|---------|---------|------|-----------|------|------|
| FRAT1; Chr10 * | Peg12 | 70 | gbp1 | 63 | 16 |
| MKRN3  | Mkrn3 | 63 | mkrn1 | 48 | 4 |
| MAGEL2 | Magel2 | 53 | ndnl2 k,α | 48 | 23 |
| NDN    | Ndu   | 82 | ndnl2 k,α | 40 | 23 |
| NPAP1  | Pom121; Chr5 * | 28 | pom121 | 24 | 10 |
| SNRPN  | Snpn  | 100 | snpα | 93 | 6 |
| SNORD107 | Snord 107 | - |  - | - |
| SNORD64 | Snord 64 | - |  - | - |
| SNORD116@27 | Snord116@27 | - |  - | - |
| SNORD115@41 | Snord115@130 | - |  - | - |
| SNORD108 | - | - |  - | - |
| SNORD109A | - | - |  - | - |
| SNORD109B | - | - |  - | - |

% aa, percent amino acid identity to human; Chr., Chromosome; *, ortholog is located outside the PWS-associated region; -, no identified orthologous gene; &, ndnl2 is orthologous to both MAGEL2 and NDN; +, zebrafish mutant has been generated; @, copy numbers according to [11].
## Table 3

Phenotypic characteristics of chromosomal deletion mouse models of PWS.

| Failure to Thrive/Early Fatality                                                                 | No Observable Abnormal Phenotype                                      |
|-------------------------------------------------------------------------------------------------|---------------------------------------------------------------------|
| Maternal duplication and paternal deletion in PWS region [36]                                  | Deletion of exon 1 of Snrpn [39]                                    |
| 6.8 Mb deletion spanning PWS and AS regions [37]                                               | Deletion of Snrpn exon 2 [40]                                       |
| Deletion spanning from Snrpn to Ube3a [40]                                                     | Double deletion of Snrpn exon 2 and Ube3a [40]                      |
| Deletion of Snrpn exons 1–6 and distal portion of IC [41]                                       | Deletion of Snrpn exon 6, parts of exons 5 and 7 [41]               |
| 4.8 kB deletion removing exon 1 of Snrpn and most of the differentially methylated region 1 (DMR1) [39] |                                                                      |

*Diseases. Author manuscript; available in PMC 2016 November 15.*
Table 4

Phenotypic characteristics of single gene or gene cluster deletion mouse models of PWS.

| Endo-Phenotype                        | Ndn [43] | Magel2 [42,44,46] | Snord116 [45] |
|---------------------------------------|---------|-------------------|---------------|
| Reduced oxytocin expression           | Yes     | -                 | -             |
| Postnatal growth retardation          | X       | Yes               | Yes           |
| Increased anxiety                     | -       | Yes               | Yes           |
| Respiratory distress                  | Yes     | -                 | -             |
| Skin scraping                         | Yes     | -                 | -             |
| Improved spatial memory and learning  | Yes     | X                 | X             |
| Altered circadian output              | -       | Yes               | -             |
| Impaired fertility                    | X       | Yes               | X             |
| Increased fat mass                    | X       | Yes               | X             |
| Hyperphagia                           | -       | X                 | Yes           |

Yes, phenotype was present; X, phenotype was absent; -, phenotype was not assessed.